ABOUT

The 2024 Nobel Prize in Physiology or Medicine was awarded to Dr. Victor Ambros and Dr. Gary Ruvkun for their discovery of microRNA (miRNA) and its role in gene regulation. This pioneering work has opened new avenues for understanding gene regulation and disease mechanisms, positioning miRNA-based therapies at the forefront of medical innovation.  Dr. Xiangfei "Scott" Cheng, the sole inventor of miRNA chimeric molecules, is dedicated to applying these innovations to develop therapies for traumatic brain injury (TBI), cancers, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, and other conditions. These groundbreaking molecules are currently patent-pending in the USA. To save patients' lives, he founded Allphild Inc to advance these innovative molecules into life-saving drugs.  Additionally, the company is dedicated to develop immunotherapy, cell and gene therapies, and small-molecule therapies for cancers and other diseases. 

Allphild Inc stands at the forefront of biopharmaceutical innovation, committed to transforming lives through cutting-edge research and development. Specializing in novel drug therapies for traumatic brain injury (TBI), cancers, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, organ transplantation, and vaccine development, we are driven by our mission to save lives.

Our commitment to innovation drives us to explore novel therapeutic solutions for the most challenging medical conditions. With a passionate team of world-class scientists and researchers, we tirelessly pursue breakthroughs that redefine therapy across multidisciplinary fields. Leveraging the latest advancements in biotechnology, we strive to push the boundaries of what’s possible in healthcare. Explore our website to learn more about our groundbreaking research and development.